Table 2.

Response to therapy (N = 46)

Response	All		Treated with RUX and AZA (n = 41)		Patients with splenomegaly* (n = 34)		Time to response†
	No.	%‡	No.	%‡	No.	%‡	Months	Range
Individual responses§
PR overall‖	2	4	2	5	2	6	14.5	10-19
PR including clinical improvement for spleen and hemoglobin	1	2	1	2	1	3	19
PR including clinical improvement for TSS, spleen, and hemoglobin	1	2	1	2	1	3	10
Clinical improvement overall	31	67	31	76	21	62	4	0.3-15
Clinical improvement for TSS and spleen	9	20	9	22	9	26	5
Clinical improvement for spleen; cytogenetic CR	2	4	2	5	2	6	5.4
Clinical improvement for TSS; cytogenetic CR	1	2	1	2	0		5.5
Clinical improvement for TSS and hemoglobin	2	4	2	5	1	3	4	0.7-15
Clinical improvement for TSS only	11	24	11	27	3	9	1.8	0.5-10
Clinical improvement for spleen only	6	13	6	15	8	24	1.5	0.3-12
NR/SD	11	24	8	20	9	26	—
PD (AML)	2	4	2	5	2	6	—
Response types¶
Clinical improvement for spleen	21	47	19	46	21	62	1.8	0.5-18
Clinical improvement for TSS	22	48	16	54	16	47	2	0.7-16
Clinical improvement for hemoglobin	4	9	3	7	3	9	5.8	1.1-15
Clinical improvement for cytogenetics	3	7	3	7	3	9	6	6-12

NR, no response; PD, progressive disease; PR, partial remission; SD, stable disease.

^*Splenomegaly ≥5 cm below costal margin.

^†In case of combined response, time to response is based on time to the longest response. Time to response is calculated as median for 2 or more responders, and as the best time to response for single responder.

^‡Percentages are calculated from all patients at risk.

^§Individual best response per IWG-MRT criteria.

^‖Both PRs happened after AZA was added with achievement of clinical improvement in spleen length (entire spleen response after AZA [n = 1]; continuing improvement in spleen length [n = 1]).

^¶Summarizes overall frequency of each type of response.